|
See related Reyataz cap information |
|
|
|
Manufacturer |
Bristol-Myers Squibb |
|
Distributor |
Hong Kong: DKSH |
|
Contents |
Atazanavir sulfate |
|
Indications |
In combination w/ other antiretroviral agents for the treatment of HIV-1 infection.
Click to view Reyataz detailed prescribing infomation |
|
Dosage |
Adult therapy-naive patient Reyataz 300 mg w/ ritonavir 100 mg (all as single daily dose) or Reyataz 400 mg once daily. Co-administration w/ tenofovir Reyataz 300 mg w/ ritonavir 100 mg & tenofovir 300 mg (all as single daily dose). Co-administration w/ efavirenz Reyataz 400 mg w/ ritonavir 100 mg & efavirenz 600 mg (all as single daily dose). Therapy-experienced patient Reyataz 300 mg w/ ritonavir 100 mg (all as single daily dose). Co-administration w/ tenofovir Reyataz 300 mg w/ ritonavir 100 mg & tenofovir 300 mg (all as single daily dose).
Click to view Reyataz detailed prescribing infomation |
|
Overdosage |
View Reyataz overdosage for action to be taken in the event of an overdose. |
|
Administration |
Should be taken with food (Swallow whole, do not chew/crush/open.). |
|
Contraindications |
Hypersensitivity. Severe hepatic impairment. End-stage renal disease managed w/ hemodialysis. Lactation. Childn <3 mth.
Click to view Reyataz detailed prescribing infomation |
|
Warnings |
For additional cautionary notes to warn of the potential risk of using the medicine... click to view Reyataz detailed prescribing infomation |
|
Special Precautions |
Patients w/ preexisting conduction system disease; rash; diabetes/hyperglycemia; hyperbilirubinemia. Hepatic impairment, hemophilia type A & B. Nephrolithiasis. Patients on combination antiretroviral therapy. Pregnancy. Elderly.
Click to view Reyataz detailed prescribing infomation |
|
Adverse Drug Reactions |
Nausea, jaundice/scleral icterus, rash, headache, abdominal pain, vomiting, insomnia, peripheral neurologic symptoms, dizziness, myalgia, diarrhea, depression, fever.
View ADR Monitoring Form |
|
Drug Interactions |
Drugs that should not be co-administered w/ Reyataz: Ergot derivatives eg dihydroergotamine, ergotamine, ergonovine, methylergonovine. Pimozide, cisapride, triazolam, midazolam, irinotecan, indinavir, lovastatin, simvastatin, rifampin, St. John's wort. Drugs that may require or may cause alteration in dose or regimen if co-administered w/ Reyataz: Didanosine-buffered formulations, tenofovir, efavirenz, nevirapine, saquinavir, ritonavir, antacids & buffered medications, amiodarone, bepridil, systemic lidocaine, quinidine, warfarin, TCA, trazodone, ketoconazole, itraconazole, voriconazole, rifabutin, Ca-channel blockers, atorvastatin, rosuvastatin, H2-receptor antagonists, ethinyl estradiol & norgestimate or norethindrone, cyclosporin, sirolimus, tacrolimus, fluticasone, clarithromycin, buprenorphine, sildenafil, tadalafil, vardenafil, omeprazole.
View more drug interactions with Reyataz |
|
Pregnancy Category (US FDA) |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
|
Storage |
View Reyataz storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Reyataz description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Reyataz mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
